The positive readout from the CheckMate-76K study means that Opdivo (nivolumab ... (pembrolizumab), which was approved for adjuvant treatment of melanoma last December. Securing approvals in ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

12-16 Patients with stage IIB/C and stage III melanoma, despite radical surgery, have a high risk for relapse within 5 years of their initial treatment. Historically, interferon-alpha-2B has been ...

The European Medicines Agency has approved PD-1 inhibitor Keytruda (pembrolizumab) as an adjuvant therapy for adults who have undergone surgery to remove melanoma, based on clinical results ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

Bristol Myers Squibb’s (BMJ) Phase III Relativity-098 trial examining its stage III-IV melanoma ... the impact of adjuvant immunotherapy alongside Opdualag, its nivolumab and relatlimab fixed ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

Those who had residual disease after neoadjuvant nivolumab proceeded to surgery and adjuvant therapy. Pathologic or clinical complete response rate served as the primary endpoint. Secondary ...